Mylan has announced the launch of Repaglinide Tablets, the generic version of Novo Nordisk’s Prandin.
RELATED: Endocrine Disorders Resource Center
Repaglinide is an oral meglitinide used in the management of non-insulin dependent diabetes mellitus (type 2). Repaglinide reduces blood glucose levels by stimulating the release of insulin from the pancreas and closing ATP-dependent potassium channels in the ß-cell membrane through binding at characterizable sites. As the potassium channel blockade depolarizes the ß-cell, the calcium channels are opened and the increased calcium induces insulin secretion.
Mylan’s Repaglinide Tablets are available in 0.5mg, 1mg, and 2mg strengths.
For more information call (800) RX-MYLAN or visit Mylan.com.
